Tempus AI achieves strong revenue growth and beats expectations, but ongoing losses and execution risks temper enthusiasm.

Tempus AI’s TEM stock has surged nearly 13% since its second-quarter 2025 earnings release. The quarter saw strong top-line ...

Although shares have retreated from their all-time high, those who bought shares one year ago are still looking at growth in ...

The stock of Tempus AI (NASDAQ: TEM) gave back some of its gains after surging early in Friday's trading, but it still ended ...

Tempus AI (NASDAQ:TEM) stock sees a 9% pre-market gain as the company raises its 2025 revenue outlook amid strong Q2 ...

Tempus AI TEM stock saw a positive improvement to its Relative Strength (RS) Rating on Thursday, rising from 66 to 78. Please ...

On fundamentals, Medtronic’s current market capitalization is $119 billion. Over the last twelve months, the company ...

After Tempus AI’s Q2 earnings release, analysts at Morgan Stanley increased their price target on the stock from $65 to $68.

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting ...

Analysts expect the Chicago, Illinois-based company to report a quarterly loss at 25 cents per share, versus a year-ago loss ...

It marks the second time Tempus AI has received FDA clearance for a cardiovascular product suite.